Efficacy and safety of obinutuzumab in systemic lupus erythematosus patients with secondary non-response to rituximab

奥比努图库单抗 医学 美罗华 相伴的 内科学 贝里穆马布 CD20 中性粒细胞减少症 胃肠病学 免疫学 淋巴瘤 抗体 化疗 B细胞 B细胞激活因子
作者
Jack Arnold,Shouvik Dass,Sarah Twigg,Colin Jones,Ben Rhodes,Peter Hewins,Mithun Chakravorty,Phil Courtney,Michael R. Ehrenstein,Yuzaiful Md Yusof,Edward M Vital
出处
期刊:Rheumatology [Oxford University Press]
卷期号:61 (12): 4905-4909 被引量:9
标识
DOI:10.1093/rheumatology/keac150
摘要

Secondary inefficacy with infusion reactions and anti-drug antibodies (secondary non-depletion nonresponse, 2NDNR) occurs in 14% of SLE patients receiving repeated rituximab courses. We evaluated baseline clinical characteristics, efficacy and safety of obinutuzumab, a next-generation humanized type-2 anti-CD20 antibody licensed for haematological malignancies in SLE patients with 2NDNR to rituximab.We collated data from SLE patients receiving obinutuzumab for secondary non-response to rituximab in BILAG centres. Disease activity was assessed using BILAG-2004, SLEDAI-2K and serology before, and 6 months after, obinutuzumab 2× 1000 mg infusions alongside methylprednisolone 100 mg.All nine patients included in the study received obinutuzumab with concomitant oral immunosuppression. At 6 months post-obinutuzumab, there were significant reductions in median SLEDAI-2K from 12 to 6 (P = 0.014) and total BILAG-2004 score from 21 to 2 (P = 0.009). Complement C3 and dsDNA titres improved significantly (both P = 0.04). Numerical, but not statistically significant improvements were seen in C4 levels. Of 8/9 patients receiving concomitant oral prednisolone at baseline (all >10 mg/day), 5/8 had their dose reduced at 6 months. Four of nine patients were on 5 mg/day and were in Lupus Low Disease Activity State following obinutuzumab. After obinutuzumab, 6/9 patients with peripheral B cell data achieved complete depletion, including 4/4 assessed with highly sensitive assays. Of the nine patients, one obinutuzumab non-responder required CYC therapy. One unvaccinated patient died from COVID-19.Obinutuzumab appears to be effective and steroid-sparing in renal and non-renal SLE patients with secondary non-response to rituximab. These patients have severe disease with few treatment options but given responsiveness to B cell depletion, switching to humanized type-2 anti-CD20 therapy is a logical approach.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
我是老大应助令散内方采纳,获得10
2秒前
流星雨完成签到 ,获得积分10
3秒前
8秒前
雪山飞龙发布了新的文献求助10
9秒前
温柔梦松发布了新的文献求助10
13秒前
研友_GZ3zRn完成签到 ,获得积分0
15秒前
肥羊七号完成签到 ,获得积分10
21秒前
闪闪的斑马完成签到,获得积分10
23秒前
皮皮完成签到 ,获得积分10
24秒前
云泥完成签到 ,获得积分10
25秒前
电子屎壳郎完成签到,获得积分10
32秒前
多么完美的一天完成签到,获得积分10
47秒前
果酱的奥特曼完成签到,获得积分10
49秒前
冬叶完成签到,获得积分10
58秒前
秋风暖暖完成签到 ,获得积分0
1分钟前
Skywalker完成签到,获得积分10
1分钟前
Dave完成签到 ,获得积分10
1分钟前
瓜瓜猫完成签到 ,获得积分10
1分钟前
1分钟前
乐宝完成签到,获得积分10
1分钟前
学呀学完成签到 ,获得积分10
1分钟前
yY0720发布了新的文献求助30
1分钟前
跪斗丶完成签到 ,获得积分10
1分钟前
温柔梦松完成签到,获得积分20
1分钟前
reflux应助科研通管家采纳,获得10
1分钟前
yY0720完成签到,获得积分10
1分钟前
1分钟前
墩墩完成签到,获得积分20
2分钟前
阳阳阳发布了新的文献求助10
2分钟前
阳阳阳完成签到,获得积分10
2分钟前
丸子完成签到 ,获得积分10
2分钟前
wxnice完成签到,获得积分10
2分钟前
木子三少完成签到,获得积分10
2分钟前
阿城完成签到 ,获得积分10
2分钟前
韧迹完成签到 ,获得积分10
2分钟前
无辜的行云完成签到 ,获得积分0
3分钟前
研友_LmgOaZ完成签到 ,获得积分0
3分钟前
ned完成签到,获得积分10
3分钟前
Avicii完成签到 ,获得积分10
3分钟前
仇夜羽完成签到 ,获得积分10
3分钟前
高分求助中
Un calendrier babylonien des travaux, des signes et des mois: Séries iqqur îpuš 1036
Sustainable Land Management: Strategies to Cope with the Marginalisation of Agriculture 1000
Corrosion and Oxygen Control 600
Python Programming for Linguistics and Digital Humanities: Applications for Text-Focused Fields 500
Heterocyclic Stilbene and Bibenzyl Derivatives in Liverworts: Distribution, Structures, Total Synthesis and Biological Activity 500
重庆市新能源汽车产业大数据招商指南(两链两图两池两库两平台两清单两报告) 400
Division and square root. Digit-recurrence algorithms and implementations 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2546139
求助须知:如何正确求助?哪些是违规求助? 2175672
关于积分的说明 5600244
捐赠科研通 1896399
什么是DOI,文献DOI怎么找? 946273
版权声明 565379
科研通“疑难数据库(出版商)”最低求助积分说明 503557